Foresite Capital Management IV, LLC
CIK 1704132 · View on SEC EDGAR ↗
- Portfolio value
- $290.2M
- Positions
- 6
- As of
- June 30, 2026
Portfolio value QoQ: +22.4% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 6
- Effective number of positions
- 2.6
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 10.74% Est. buys $28,299,666 · sells $29,096,979
Median holding: 4.0 quarters Tracked Q4 2024–Q2 2026 · 54.5% still held
- New positions
- 1
- Increased
- 2
- Decreased
- 0
- Closed
- 3
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +60.8% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.6% · Options excluded: 0.0%
Sector breakdown
Full portfolio 6 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris N.V. - Ordinary Shares | $165,243,331 | 56.95% | 4,778,581 | $30,248,418 | |||
| CYTK Cytokinetics, Incorporated - Common Stock | $60,884,867 | 20.98% | 714,695 | $27,712,694 | Up ×2 | ||
| EIKN Eikon Therapeutics, Inc. - Common Stock | $25,365,050 | 8.74% | 1,943,682 | $4,800,894 | |||
| RLAY Relay Therapeutics, Inc. - Common Stock | $23,387,500 | 8.06% | 1,250,000 | $13,437,500 | Up ×1 | ||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $9,657,600 | 3.33% | 160,000 | $353,600 | |||
| CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $5,613,000 | 1.93% | 150,000 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| CRNX | $5,613,000 | 150,000 | 1.93% |
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| LYEL | June 30, 2026 | 800,399 | $16,056,004 | 13.0% |
| LYELXXXX | June 30, 2025 | 16,007,999 | $8,612,303 | No longer tracked |
| ALEC | June 30, 2026 | 3,887,200 | $8,357,480 | 13.2% |
| KURA | Sept. 30, 2025 | 816,882 | $4,713,409 | 33.2% |
| MAZE | June 30, 2026 | 156,901 | $4,683,495 | -2.6% |